IGAN
Clinical trials for IGAN explained in plain language.
Never miss a new study
Get alerted when new IGAN trials appear
Sign up with your email to follow new studies for IGAN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Drug trial halted after testing for rare kidney conditions
Disease control TerminatedThis study tested an experimental drug called OMS721 (narsoplimab) in adults with four serious kidney diseases. The main goals were to check the drug's safety and see if it could reduce harmful protein in the urine, a key sign of kidney damage. The trial was terminated early and …
Matched conditions: IGAN
Phase: PHASE2 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug trial aims to protect kidneys in autoimmune diseases
Disease control TerminatedThis study tested an investigational drug, ALXN2050, in adults with two serious kidney diseases: lupus nephritis and IgA nephropathy. The goal was to see if adding ALXN2050 to standard care could better reduce protein in the urine and protect long-term kidney function. The trial …
Matched conditions: IGAN
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC